Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Goodwill & Intangibles (2017 - 2025)

Avalo Therapeutics' Goodwill & Intangibles history spans 9 years, with the latest figure at $10.5 million for Q4 2025.

  • For Q4 2025, Goodwill & Intangibles changed 0.02% year-over-year to $10.5 million; the TTM value through Dec 2025 reached $10.5 million, changed 0.02%, while the annual FY2025 figure was $10.5 million, 0.02% changed from the prior year.
  • Goodwill & Intangibles reached $10.5 million in Q4 2025 per AVTX's latest filing, roughly flat from $10.5 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $15.6 million in Q1 2021 to a low of $10.5 million in Q4 2025.
  • Average Goodwill & Intangibles over 5 years is $12.8 million, with a median of $14.4 million recorded in 2022.
  • Peak YoY movement for Goodwill & Intangibles: rose 1.7% in 2021, then fell 27.11% in 2023.
  • A 5-year view of Goodwill & Intangibles shows it stood at $14.4 million in 2021, then decreased by 0.26% to $14.4 million in 2022, then dropped by 27.11% to $10.5 million in 2023, then changed by 0.0% to $10.5 million in 2024, then decreased by 0.02% to $10.5 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Goodwill & Intangibles are $10.5 million (Q4 2025), $10.5 million (Q3 2025), and $10.5 million (Q2 2025).